Abstract
Masitinib is the first veterinary drug recently approved in Europe to treat mast cell tumours in dogs (Hahn et al. JVIM, Masivet). This inhibitor is selective and highly efficient in blocking c-Kit, PDGFR, and Lyn tyrosine kinase activities. It showed good efficacy and acceptable toxicity in several animal studies such as mice, rats, rabbits and dogs (Dubreuil P, et al. submitted, and Hahn et al. (J Vet Intern Med 22(6):8, 2008)). C-kit is a tyrosine kinase receptor that plays a critical role in the biology of mast cells including differentiation, survival, migration and cytokine/mediator release. Mast cells are involved in a number of allergy-and immune-related diseases in cats such as asthma (Reinero Carol et al. Vet Immunol Immunopathol 121(3–4):9, 2008), inflammatory bowel disease, (Janeczko et al. Vet Mic 128(1–2):15, 2008), and feline mast cell tumours (Rassnick et al. J Am Vet Med Assoc 232(8):1200–1205, 2008). Therefore, there might be a strong rationale to use masitinib in these indications. Here, we report the results of a preliminary pharmacokinetic study of masitinib in cats which showed a good bioavailability of ~60% in both sexes. We propose that an oral dose of 10–15 mg/kg masitinib is appropriate to achieve adequate plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Corcoran BM, Foster D, Luis Funetes V. Feline astma syndrome: a retrospective study of the clinical presentation in 29 cats. J Small Anim Pract 1995;36:7. doi:10.1111/j.1748-5827.1995.tb02787.x
Dahm Rebecca LK. Mast cell disease in dogs and cats: an overview. Veterianry clinical pathology clerkship program 2001.
(EPAR) EPAR. Masivet. In. 17 November 2008 ed; 2008.
Foster SF, Allan G, Martin P, Robertson ID and Malik R. Twenty-five cases of feline bronchial disease (1995–2000). J Feline Med Surg. 2004;6(3):7
Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil, P, Moussy A, Hermine O. Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. J Vet Intern Med 2008;22(6):8. doi:10.1111/j.1939-1676.2008.0190.x
Iba Yoshinori, Shirai Maiko, Dei Chiaki, Hirata Takahiro, Harada Chika, Masukawa Tohru. Involvement of mast cells in the regulation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteases-1 in 12-O-tetradecanoylphorbolacetate-induced inflammation in mice. Int. Immunopharmacol. 2007;7(5):6.
Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol. 2006;114(1–2):5. doi:10.1016/j.vetimm.2006.07.004
S. Janeczko, D. Atwater, E. Bogel, A. Greiter-Wilke, A. Gerold, M. Baumgart, H. Bender, P.L. McDonough, S.P. McDonough, R.E. Goldstein, K.W. Simpson. The relationship of mucosal bacteria to duodenal histopathology, cytokine mRNA, and clinical disease activity in cats with inflammatory bowel disease. Vet Mic 2008;128(1–2):15.
Kirschvink N, Leemans J, Delvaux F, Snaps F, Clercx C, Gustin P. Functional, inflammatory and morphological charaterisation of a cat model of allergic airway inflammation. The Veterinary Journal 2007;174:12.
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005;23(1):16–43. doi:10.1634/stemcells.2004-0117
Little S. The Pulmonary Distribution of a Nebulized Radiopharmaceutical in Awake Cats Winn Feline Foundation Progress Report 2001;<http://www.winnfelinehealth.org/Pages/Nebulized_Drugs_for_Asthma.pdf>.
Max’s House. Tumors of the skin and subcutaneous tissues. Max’s House Feline Health & Behavior Monthly Newsletter 2008;webproject@maxshouse.com.
Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. Curr Drug Targets Inflamm Allergy 2005;4(2):4. doi:10.2174/1568010053586246
Rassnick KM, Williams LE, Kristal O, Al-Sarraf R, Baez JL, Zwahlen CH, et al. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999–2005). J Am Vet Med Assoc 2008;232(8):1200–5. doi:10.2460/javma.232.8.1200
Reinero Carol, Cohn Leah, Delgado Cherlene, Spinka Christine, Schooley Elizabeth, DeClue Amy. Adjuvated rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet Immunol Immunopathol. 2008;121(3-4):9.
Roosje PJ, Koeman J, Thepen T, Willemse T. Mast Cells and Eosinophiles in Feline Allergic Dermatitis: A Quantitative Analysis. J. Comp. Path. 2004;131:8. doi:10.1016/j.jcpa.2004.01.005
Waly NE, Stokes C, Gruffydd-Jones TJ, Day MJ. Immune cell populations in the duodenal mucosa of cats with inflammatory bowel disease. J Vet Intern Med 2004;18(6):10. doi:10.1892/0891-6640(2004)18<816:ICPITD>2.0.CO;2
Potential conflict of interest
This study was outsourced by AB Science to: ADME Bioanalyses, 75, Chemin de Sommières – 30310 VERGEZE, France. FB, TB, and AM are employed by AB Science.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bellamy, F., Bader, T., Moussy, A. et al. Pharmacokinetics of masitinib in cats. Vet Res Commun 33, 831–837 (2009). https://doi.org/10.1007/s11259-009-9231-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11259-009-9231-6